Conclusions
CIDP is a disabling immune-mediated polyradiculoneuropathy with a typical phenotype and atypical variants, that involves both demyelination and axonal degeneration, with the balance being determined by disease duration and severity37.
The task of correctly diagnosing CIDP is often not easy, as there are many differential diagnoses and possible mimics. However, an early and accurate diagnosis is important to initiate treatment and to prevent further nerve damage30-32.
On the other hand, the consequences of over diagnosis are not trivial. From a safety perspective, the risks assumed from immunotherapy exposure are obvious. The therapies we use to treat CIDP are not benign, nor are they (in most cases) cheap38.
This is the reason why we consider patients affected by CIDP require close follow up due to the neuronal demyelination along with axonal degeneration associated with the disease process, giving the opportunity to the medical team of adequating therapeutics and other medical interventions, according to the evolution of the symptoms, to prevent irreversible axonal degeneration.